title: Analysis of 3-year national reimbursement application data on etanercept and efalizumab for psoriasis.
authors.forename: R J B
authors.initials: RJ
authors.lastname: Driessen
authors.forename: E M G J
authors.initials: EM
authors.lastname: de Jong
authors.forename: M A
authors.initials: MA
authors.lastname: de Rie
authors.forename: G W
authors.initials: GW
authors.lastname: Salemink
authors.forename: P C M
authors.initials: PC
authors.lastname: van de Kerkhof
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000191:economics*; D061067:Antibodies, Monoclonal, Humanized; D016527:Drug Costs; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000191:economics*; D008297:Male; D008875:Middle Aged; D009426:Netherlands; D011565:Psoriasis / Q000188:drug therapy* / Q000191:economics*; D012051:Reimbursement Mechanisms / Q000706:statistics & numerical data*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; C472181:efalizumab